GrippeCanadaV3, Main, Exploration, bibRecord, 000135

Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada.

Identifieur interne : 000135 ( Main/Exploration ); précédent : 000134; suivant : 000136

Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada.

Auteurs : Ahsan Chaudhry [Canada] ; Nathalie Bastien [Canada] ; Yan Li [Canada] ; Allison Scott [Canada] ; Kanti Pabbaraju [Canada] ; Douglas Stewart [Canada] ; Sallene Wong [Canada] ; Steven J. Drews [Canada]

Source :

Influenza and other respiratory viruses [ 1750-2659 ] ; 2016.

RBID : pubmed:27442795

Descripteurs français

KwdFr :
- Adulte d'âge moyen, Alberta (épidémiologie), Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Charge virale (), Grippe humaine (traitement médicamenteux), Grippe humaine (virologie), Grippe humaine (épidémiologie), Humains, Mutation, Mâle, Oséltamivir (pharmacologie), Oséltamivir (usage thérapeutique), Partie nasale du pharynx (virologie), Résistance virale aux médicaments, Saisons, Sialidase (génétique), Sous-type H3N2 du virus de la grippe A (), Sous-type H3N2 du virus de la grippe A (génétique), Sous-type H3N2 du virus de la grippe A (isolement et purification), Sujet immunodéprimé, Zanamivir (usage thérapeutique).
MESH :
- génétique : Sialidase, Sous-type H3N2 du virus de la grippe A.
- isolement et purification : Sous-type H3N2 du virus de la grippe A.
- pharmacologie : Antiviraux, Oséltamivir.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Antiviraux, Oséltamivir, Zanamivir.
- virologie : Grippe humaine, Partie nasale du pharynx.
- épidémiologie : Alberta, Grippe humaine.
- Adulte d'âge moyen, Charge virale, Humains, Mutation, Mâle, Résistance virale aux médicaments, Saisons, Sous-type H3N2 du virus de la grippe A, Sujet immunodéprimé.

English descriptors

KwdEn :
- Alberta (epidemiology), Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Drug Resistance, Viral, Humans, Immunocompromised Host, Influenza A Virus, H3N2 Subtype (drug effects), Influenza A Virus, H3N2 Subtype (genetics), Influenza A Virus, H3N2 Subtype (isolation & purification), Influenza, Human (drug therapy), Influenza, Human (epidemiology), Influenza, Human (virology), Male, Middle Aged, Mutation, Nasopharynx (virology), Neuraminidase (genetics), Oseltamivir (pharmacology), Oseltamivir (therapeutic use), Seasons, Viral Load (drug effects), Zanamivir (therapeutic use).
MESH :
- chemical , genetics : Neuraminidase.
- chemical , pharmacology : Antiviral Agents, Oseltamivir.
- drug effects : Influenza A Virus, H3N2 Subtype, Viral Load.
- drug therapy : Influenza, Human.
- epidemiology : Alberta, Influenza, Human.
- genetics : Influenza A Virus, H3N2 Subtype.
- isolation & purification : Influenza A Virus, H3N2 Subtype.
- chemical , therapeutic use : Antiviral Agents, Oseltamivir, Zanamivir.
- virology : Influenza, Human, Nasopharynx.
- Drug Resistance, Viral, Humans, Immunocompromised Host, Male, Middle Aged, Mutation, Seasons.

Abstract

This manuscript describes the identification of an oseltamivir-resistant influenza A (H3N2) virus in a respiratory specimen collected from an immunocompromised patient in Alberta, Canada, during the 2014-2015 influenza season. Following treatment with oseltamivir, neuraminidase (NA) gene sequencing indicated the presence of an R292K mutation. Phenotypic susceptibility testing by the NA-Star assay indicated a highly reduced inhibition by oseltamivir and normal inhibition by zanamivir. The use of zanamivir following identification of the oseltamivir-resistant strain, combined with a partial immune reconstitution, was followed by a suggested decrease in the nasopharyngeal viral load in the nasopharynx and clinical improvement of the patient.

DOI: 10.1111/irv.12415
PubMed: 27442795

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000141
to stream Main, to step Curation: 000141

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada.</title>
<author><name sortKey="Chaudhry, Ahsan" sort="Chaudhry, Ahsan" uniqKey="Chaudhry A" first="Ahsan" last="Chaudhry">Ahsan Chaudhry</name>
<affiliation wicri:level="4"><nlm:affiliation>Departments of Oncology and Medicine, University of Calgary, Calgary, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Departments of Oncology and Medicine, University of Calgary, Calgary, AB</wicri:regionArea>
<orgName type="university">Université de Calgary</orgName>
<placeName><settlement type="city">Calgary</settlement>
<region type="state">Alberta</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name>
<affiliation wicri:level="1"><nlm:affiliation>National Microbiology Laboratory, Winnipeg, MB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>National Microbiology Laboratory, Winnipeg, MB</wicri:regionArea>
<wicri:noRegion>MB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name>
<affiliation wicri:level="1"><nlm:affiliation>National Microbiology Laboratory, Winnipeg, MB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>National Microbiology Laboratory, Winnipeg, MB</wicri:regionArea>
<wicri:noRegion>MB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Scott, Allison" sort="Scott, Allison" uniqKey="Scott A" first="Allison" last="Scott">Allison Scott</name>
<affiliation wicri:level="1"><nlm:affiliation>Surveillance and Assessment, Accountability and Performance, Edmonton, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Surveillance and Assessment, Accountability and Performance, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pabbaraju, Kanti" sort="Pabbaraju, Kanti" uniqKey="Pabbaraju K" first="Kanti" last="Pabbaraju">Kanti Pabbaraju</name>
<affiliation wicri:level="1"><nlm:affiliation>ProvLab Alberta (Calgary), Calgary, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>ProvLab Alberta (Calgary), Calgary, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stewart, Douglas" sort="Stewart, Douglas" uniqKey="Stewart D" first="Douglas" last="Stewart">Douglas Stewart</name>
<affiliation wicri:level="4"><nlm:affiliation>Departments of Oncology and Medicine, University of Calgary, Calgary, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Departments of Oncology and Medicine, University of Calgary, Calgary, AB</wicri:regionArea>
<orgName type="university">Université de Calgary</orgName>
<placeName><settlement type="city">Calgary</settlement>
<region type="state">Alberta</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wong, Sallene" sort="Wong, Sallene" uniqKey="Wong S" first="Sallene" last="Wong">Sallene Wong</name>
<affiliation wicri:level="1"><nlm:affiliation>ProvLab Alberta (Calgary), Calgary, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>ProvLab Alberta (Calgary), Calgary, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Drews, Steven J" sort="Drews, Steven J" uniqKey="Drews S" first="Steven J" last="Drews">Steven J. Drews</name>
<affiliation wicri:level="1"><nlm:affiliation>ProvLab Alberta (Edmonton), Edmonton, AB, Canada. Steven.Drews@albertahealthservices.ca.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>ProvLab Alberta (Edmonton), Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada. Steven.Drews@albertahealthservices.ca.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27442795</idno>
<idno type="pmid">27442795</idno>
<idno type="doi">10.1111/irv.12415</idno>
<idno type="wicri:Area/Main/Corpus">000141</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000141</idno>
<idno type="wicri:Area/Main/Curation">000141</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000141</idno>
<idno type="wicri:Area/Main/Exploration">000141</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada.</title>
<author><name sortKey="Chaudhry, Ahsan" sort="Chaudhry, Ahsan" uniqKey="Chaudhry A" first="Ahsan" last="Chaudhry">Ahsan Chaudhry</name>
<affiliation wicri:level="4"><nlm:affiliation>Departments of Oncology and Medicine, University of Calgary, Calgary, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Departments of Oncology and Medicine, University of Calgary, Calgary, AB</wicri:regionArea>
<orgName type="university">Université de Calgary</orgName>
<placeName><settlement type="city">Calgary</settlement>
<region type="state">Alberta</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name>
<affiliation wicri:level="1"><nlm:affiliation>National Microbiology Laboratory, Winnipeg, MB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>National Microbiology Laboratory, Winnipeg, MB</wicri:regionArea>
<wicri:noRegion>MB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name>
<affiliation wicri:level="1"><nlm:affiliation>National Microbiology Laboratory, Winnipeg, MB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>National Microbiology Laboratory, Winnipeg, MB</wicri:regionArea>
<wicri:noRegion>MB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Scott, Allison" sort="Scott, Allison" uniqKey="Scott A" first="Allison" last="Scott">Allison Scott</name>
<affiliation wicri:level="1"><nlm:affiliation>Surveillance and Assessment, Accountability and Performance, Edmonton, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Surveillance and Assessment, Accountability and Performance, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pabbaraju, Kanti" sort="Pabbaraju, Kanti" uniqKey="Pabbaraju K" first="Kanti" last="Pabbaraju">Kanti Pabbaraju</name>
<affiliation wicri:level="1"><nlm:affiliation>ProvLab Alberta (Calgary), Calgary, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>ProvLab Alberta (Calgary), Calgary, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stewart, Douglas" sort="Stewart, Douglas" uniqKey="Stewart D" first="Douglas" last="Stewart">Douglas Stewart</name>
<affiliation wicri:level="4"><nlm:affiliation>Departments of Oncology and Medicine, University of Calgary, Calgary, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Departments of Oncology and Medicine, University of Calgary, Calgary, AB</wicri:regionArea>
<orgName type="university">Université de Calgary</orgName>
<placeName><settlement type="city">Calgary</settlement>
<region type="state">Alberta</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wong, Sallene" sort="Wong, Sallene" uniqKey="Wong S" first="Sallene" last="Wong">Sallene Wong</name>
<affiliation wicri:level="1"><nlm:affiliation>ProvLab Alberta (Calgary), Calgary, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>ProvLab Alberta (Calgary), Calgary, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Drews, Steven J" sort="Drews, Steven J" uniqKey="Drews S" first="Steven J" last="Drews">Steven J. Drews</name>
<affiliation wicri:level="1"><nlm:affiliation>ProvLab Alberta (Edmonton), Edmonton, AB, Canada. Steven.Drews@albertahealthservices.ca.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>ProvLab Alberta (Edmonton), Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada. Steven.Drews@albertahealthservices.ca.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Influenza and other respiratory viruses</title>
<idno type="eISSN">1750-2659</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alberta (epidemiology)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Drug Resistance, Viral</term>
<term>Humans</term>
<term>Immunocompromised Host</term>
<term>Influenza A Virus, H3N2 Subtype (drug effects)</term>
<term>Influenza A Virus, H3N2 Subtype (genetics)</term>
<term>Influenza A Virus, H3N2 Subtype (isolation & purification)</term>
<term>Influenza, Human (drug therapy)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (virology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Mutation</term>
<term>Nasopharynx (virology)</term>
<term>Neuraminidase (genetics)</term>
<term>Oseltamivir (pharmacology)</term>
<term>Oseltamivir (therapeutic use)</term>
<term>Seasons</term>
<term>Viral Load (drug effects)</term>
<term>Zanamivir (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Alberta (épidémiologie)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Charge virale ()</term>
<term>Grippe humaine (traitement médicamenteux)</term>
<term>Grippe humaine (virologie)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains</term>
<term>Mutation</term>
<term>Mâle</term>
<term>Oséltamivir (pharmacologie)</term>
<term>Oséltamivir (usage thérapeutique)</term>
<term>Partie nasale du pharynx (virologie)</term>
<term>Résistance virale aux médicaments</term>
<term>Saisons</term>
<term>Sialidase (génétique)</term>
<term>Sous-type H3N2 du virus de la grippe A ()</term>
<term>Sous-type H3N2 du virus de la grippe A (génétique)</term>
<term>Sous-type H3N2 du virus de la grippe A (isolement et purification)</term>
<term>Sujet immunodéprimé</term>
<term>Zanamivir (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Oseltamivir</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H3N2 Subtype</term>
<term>Viral Load</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Alberta</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H3N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Sialidase</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H3N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H3N2 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Oséltamivir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Oseltamivir</term>
<term>Zanamivir</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
<term>Oséltamivir</term>
<term>Zanamivir</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
<term>Partie nasale du pharynx</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
<term>Nasopharynx</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Alberta</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Resistance, Viral</term>
<term>Humans</term>
<term>Immunocompromised Host</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Mutation</term>
<term>Seasons</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Charge virale</term>
<term>Humains</term>
<term>Mutation</term>
<term>Mâle</term>
<term>Résistance virale aux médicaments</term>
<term>Saisons</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
<term>Sujet immunodéprimé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This manuscript describes the identification of an oseltamivir-resistant influenza A (H3N2) virus in a respiratory specimen collected from an immunocompromised patient in Alberta, Canada, during the 2014-2015 influenza season. Following treatment with oseltamivir, neuraminidase (NA) gene sequencing indicated the presence of an R292K mutation. Phenotypic susceptibility testing by the NA-Star assay indicated a highly reduced inhibition by oseltamivir and normal inhibition by zanamivir. The use of zanamivir following identification of the oseltamivir-resistant strain, combined with a partial immune reconstitution, was followed by a suggested decrease in the nasopharyngeal viral load in the nasopharynx and clinical improvement of the patient.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27442795</PMID>
<DateCompleted><Year>2017</Year>
<Month>09</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-2659</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>10</Volume>
<Issue>6</Issue>
<PubDate><Year>2016</Year>
<Month>11</Month>
</PubDate>
</JournalIssue>
<Title>Influenza and other respiratory viruses</Title>
<ISOAbbreviation>Influenza Other Respir Viruses</ISOAbbreviation>
</Journal>
<ArticleTitle>Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada.</ArticleTitle>
<Pagination><MedlinePgn>532-535</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/irv.12415</ELocationID>
<Abstract><AbstractText>This manuscript describes the identification of an oseltamivir-resistant influenza A (H3N2) virus in a respiratory specimen collected from an immunocompromised patient in Alberta, Canada, during the 2014-2015 influenza season. Following treatment with oseltamivir, neuraminidase (NA) gene sequencing indicated the presence of an R292K mutation. Phenotypic susceptibility testing by the NA-Star assay indicated a highly reduced inhibition by oseltamivir and normal inhibition by zanamivir. The use of zanamivir following identification of the oseltamivir-resistant strain, combined with a partial immune reconstitution, was followed by a suggested decrease in the nasopharyngeal viral load in the nasopharynx and clinical improvement of the patient.</AbstractText>
<CopyrightInformation>© 2016 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chaudhry</LastName>
<ForeName>Ahsan</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Departments of Oncology and Medicine, University of Calgary, Calgary, AB, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bastien</LastName>
<ForeName>Nathalie</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>National Microbiology Laboratory, Winnipeg, MB, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>National Microbiology Laboratory, Winnipeg, MB, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Scott</LastName>
<ForeName>Allison</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Surveillance and Assessment, Accountability and Performance, Edmonton, AB, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pabbaraju</LastName>
<ForeName>Kanti</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>ProvLab Alberta (Calgary), Calgary, AB, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Stewart</LastName>
<ForeName>Douglas</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Departments of Oncology and Medicine, University of Calgary, Calgary, AB, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wong</LastName>
<ForeName>Sallene</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>ProvLab Alberta (Calgary), Calgary, AB, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Drews</LastName>
<ForeName>Steven J</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo><Affiliation>ProvLab Alberta (Edmonton), Edmonton, AB, Canada. Steven.Drews@albertahealthservices.ca.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada. Steven.Drews@albertahealthservices.ca.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>08</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Influenza Other Respir Viruses</MedlineTA>
<NlmUniqueID>101304007</NlmUniqueID>
<ISSNLinking>1750-2640</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>20O93L6F9H</RegistryNumber>
<NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>L6O3XI777I</RegistryNumber>
<NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000416" MajorTopicYN="N">Alberta</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D024882" MajorTopicYN="Y">Drug Resistance, Viral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016867" MajorTopicYN="Y">Immunocompromised Host</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009305" MajorTopicYN="N">Nasopharynx</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">H3N2</Keyword>
<Keyword MajorTopicYN="Y">influenza</Keyword>
<Keyword MajorTopicYN="Y">neuraminidase inhibitors</Keyword>
<Keyword MajorTopicYN="Y">reduced susceptibility</Keyword>
<Keyword MajorTopicYN="Y">resistance</Keyword>
<Keyword MajorTopicYN="Y">sequence analysis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>07</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>7</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>9</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>7</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27442795</ArticleId>
<ArticleId IdType="doi">10.1111/irv.12415</ArticleId>
<ArticleId IdType="pmc">PMC5059956</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Euro Surveill. 2015 Jan 29;20(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25655053</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2001 Oct;146(10):1899-918</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11722013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2014 Dec;58(12):7188-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25246391</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2013 Dec;57(12):6141-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24080660</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Public Health Rep. 2013 Sep-Oct;128 Suppl 2:75-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23997307</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014 Mar 25;9(3):e92153</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24667168</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2013 Nov;7(6):904-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23551973</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2003 Feb;41(2):742-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12574276</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2015 Apr;53(4):1415-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25588658</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2008 Jul;46(7):2189-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18480230</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2015;20(45):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26608955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Sep;84(18):9427-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20631138</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Canada</li>
</country>
<region><li>Alberta</li>
</region>
<settlement><li>Calgary</li>
</settlement>
<orgName><li>Université de Calgary</li>
</orgName>
</list>
<tree><country name="Canada"><region name="Alberta"><name sortKey="Chaudhry, Ahsan" sort="Chaudhry, Ahsan" uniqKey="Chaudhry A" first="Ahsan" last="Chaudhry">Ahsan Chaudhry</name>
</region>
<name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name>
<name sortKey="Drews, Steven J" sort="Drews, Steven J" uniqKey="Drews S" first="Steven J" last="Drews">Steven J. Drews</name>
<name sortKey="Drews, Steven J" sort="Drews, Steven J" uniqKey="Drews S" first="Steven J" last="Drews">Steven J. Drews</name>
<name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name>
<name sortKey="Pabbaraju, Kanti" sort="Pabbaraju, Kanti" uniqKey="Pabbaraju K" first="Kanti" last="Pabbaraju">Kanti Pabbaraju</name>
<name sortKey="Scott, Allison" sort="Scott, Allison" uniqKey="Scott A" first="Allison" last="Scott">Allison Scott</name>
<name sortKey="Stewart, Douglas" sort="Stewart, Douglas" uniqKey="Stewart D" first="Douglas" last="Stewart">Douglas Stewart</name>
<name sortKey="Wong, Sallene" sort="Wong, Sallene" uniqKey="Wong S" first="Sallene" last="Wong">Sallene Wong</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000135 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000135 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeCanadaV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:27442795
   |texte=   Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27442795" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeCanadaV3

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 13:36:58 2020. Site generation: Sat Sep 26 07:06:42 2020

	Corpus GrippeCanadaV3
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Corpus GrippeCanadaV3

Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada.

Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki